OS Therapies Incorporated Share Price

OS Therapies Incorporated Share Price

AMEX: OSTX | Micro Cap
$1.24
-$0.05 (-4.25%) Last updated on 30 Oct, 2026 | 19:33 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

OS Therapies Incorporated Stock Performance

Open
$1.26
Prev. Close
$1.29
Circuit Range
N/A
Day Range
$1.24 - $1.26
Year Range
$1.16 - $2.25
Volume
382
Average Traded
$1.26

OS Therapies Incorporated Share Price Today

As of 30 October 2026, OS Therapies Incorporated's share price is $1.24. The stock opened at $1.26, compared to its previous close of $1.29. During today's trading session, OS Therapies Incorporated's share price traded between $1.24 and $1.26, with an average price of $1.25. Over the past 52 weeks, the stock has recorded a high of $2.25 and a low of $1.16. In terms of performance, OS Therapies Incorporated's share price has declined by 27.70% over the last six months and is down 32.43% on a year-on-year basis.

OS Therapies Incorporated Share Price Chart

Line chart of the OS Therapies Incorporated price trend over the selected period. The price fell overall, ranging from 1.24 to 1.26, ending at 1.24.
$1.24$1.26
L
Show Current Price
H

OS Therapies Incorporated Stock Fundamentals & Key Indicators

Market Cap
$36.27M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.84
Revenue (TTM)
$0.00
Return On Equity (TTM)
330.43%
Profit Margin
N/A
Debt to Equity
-0.01
Quarterly Earnings Growth YoY
-25.44%

OS Therapies Incorporated Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$6.88-$13.46-$10.40-$8.63
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-95.64%22.73%17.02%

OS Therapies Incorporated Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$0.00
Net Profit-$8.91-$28.75
Net Profit MarginN/AN/A
Income ChangeN/A-222.67%

About OS Therapies Incorporated

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.

OS Therapies Incorporated Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.57
$1.24
-23.69%
Sep 2026
$1.65
$1.63
-3.85%
Aug 2026
$1.53
$1.69
+10.46%
Jul 2026
$1.89
$1.53
-19.26%
Jun 2026
$2.17
$1.90
-11.66%
May 2026
$1.73
$2.15
+25.07%
Apr 2026
$1.40
$1.72
+22.06%
Mar 2026
$1.43
$1.41
-3.77%
Feb 2026
$1.39
$1.46
+6.57%
Jan 2026
$1.36
$1.37
-1.79%
Dec 2025
$1.75
$1.40
-22.07%
Nov 2025
$1.81
$1.79
-2.45%

OSTX Share Price FAQs